PR Newswire
MILWAUKEE, Oct. 4, 2023
MILWAUKEE, Oct. 4, 2023 /PRNewswire/ -- Ademi LLP is investigating SomaLogic (Nasdaq: SLGC) for possible breaches of fiduciary duty and other violations of law in its transaction with Standard BioTools.
Click here to learn how to join the action https://www.ademilaw.com/case/somalogic-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.
In the transaction, SomaLogic stockholders are expected to receive only 1.11 shares of Standard BioTools common stock for each share of SomaLogic common stock owned. The transaction agreement unreasonably limits competing transactions for SomaLogic by imposing a significant penalty if SomaLogic accepts a competing bid. SomaLogic insiders will receive substantial benefits as part of change of control arrangements.
We are investigating the conduct of SomaLogic's board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.
If you own SomaLogic common stock and wish to obtain additional information, please contact Guri Ademi either at [email protected] or toll-free: 866-264-3995, or https://www.ademilaw.com/case/somalogic-inc.
We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Contacts
Ademi LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001
View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-ademi-llp-investigates-whether-somalogic-inc-has-obtained-a-fair-price-in-its-transaction-with-standard-biotools-301947241.html
SOURCE Ademi LLP
